Literature DB >> 10792463

Mechanism of catabolite repression in the bgl operon of Escherichia coli: involvement of the anti-terminator BglG, CRP-cAMP and EIIAGlc in mediating glucose effect downstream of transcription initiation.

A Gulati1, S Mahadevan.   

Abstract

BACKGROUND: Expression of the bgl operon of Escherichia coli, involved in the regulated uptake and utilization of aromatic beta-glucosides, is extremely sensitive to the presence of glucose in the growth medium. We have analysed the mechanism by which glucose exerts its inhibitory effect on bgl expression.
RESULTS: Our studies show that initiation of transcription from the bgl promoter is only marginally sensitive to glucose. Instead, glucose exerts a more significant inhibition on the elongation of transcription beyond the rho-independent terminator present within the leader sequence. Transcriptional analyses using plasmids that carry mutations in bglG or within the terminator, suggest that the target for glucose-mediated repression is the anti-terminator protein, BglG. Introduction of multiple copies of bglG or the presence of mutations that inhibit its phosphorylation by Enzyme IIBgl (BglF), result in loss of glucose repression. Studies using crp, cya and crr strains show that both CRP-cAMP and the Enzyme IIAGlc (EIIAGlc) are involved in the regulation. Although transcription initiation is normal in a crp, cya double mutant, no detectable transcription is seen downstream of the terminator, which is restored by a mutation within the terminator. Transcription past the terminator is also partly restored by the addition of exogenous cAMP to glucose-grown cultures of a crp+ strain. Glucose repression is lost in the crr mutant strain.
CONCLUSIONS: The results summarized above indicate that glucose repression in the bgl operon is mediated at the level of transcription anti-termination, and glucose affects the activity of BglG by altering its phosphorylation by BglF. The CRP-cAMP complex is also involved in this regulation. The results using the crr mutant suggest a negative role for EIIAGlc in the catabolite repression of the bgl genes.

Entities:  

Mesh:

Substances:

Year:  2000        PMID: 10792463     DOI: 10.1046/j.1365-2443.2000.00322.x

Source DB:  PubMed          Journal:  Genes Cells        ISSN: 1356-9597            Impact factor:   1.891


  7 in total

1.  Translation efficiency of antiterminator proteins is a determinant for the difference in glucose repression of two β-glucoside phosphotransferase system gene clusters in Corynebacterium glutamicum R.

Authors:  Yuya Tanaka; Haruhiko Teramoto; Masayuki Inui; Hideaki Yukawa
Journal:  J Bacteriol       Date:  2010-11-12       Impact factor: 3.490

2.  Mutations that activate the silent bgl operon of Escherichia coli confer a growth advantage in stationary phase.

Authors:  Ranjna Madan; Roberto Kolter; S Mahadevan
Journal:  J Bacteriol       Date:  2005-12       Impact factor: 3.490

3.  Identification of the CRP regulon using in vitro and in vivo transcriptional profiling.

Authors:  Dongling Zheng; Chrystala Constantinidou; Jon L Hobman; Stephen D Minchin
Journal:  Nucleic Acids Res       Date:  2004-11-01       Impact factor: 16.971

4.  Sinorhizobium meliloti mutants lacking phosphotransferase system enzyme HPr or EIIA are altered in diverse processes, including carbon metabolism, cobalt requirements, and succinoglycan production.

Authors:  Catalina Arango Pinedo; Ryan M Bringhurst; Daniel J Gage
Journal:  J Bacteriol       Date:  2008-02-15       Impact factor: 3.490

5.  HPrK regulates succinate-mediated catabolite repression in the gram-negative symbiont Sinorhizobium meliloti.

Authors:  Catalina Arango Pinedo; Daniel J Gage
Journal:  J Bacteriol       Date:  2008-10-17       Impact factor: 3.490

6.  A mechanism of transposon-mediated directed mutation.

Authors:  Zhongge Zhang; Milton H Saier
Journal:  Mol Microbiol       Date:  2009-08-04       Impact factor: 3.501

7.  The Escherichia coli antiterminator protein BglG stabilizes the 5'region of the bgl mRNA.

Authors:  A Gulati; S Mahadevan
Journal:  J Biosci       Date:  2001-06       Impact factor: 2.795

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.